Reach top Journalists who write about Biogen
Quickly connect with experienced news professionals who write about Biogen, ready to cover your story or provide expert reporting. From breaking news to in-depth features, find the talent you need.
View
Biogen
paydesk has 12 reporters who cover Biogen. Our journalists are already on location, all over the world, and ready to work at a moment's notice. Our top correspondents who cover Biogen are George W Citroner and Elizabeth Dickinson. Use our journalist directory to find an Biogen member to work for you.
Journalists Who Cover Biogen
George W Citroner
My work has appeared in Fox News, Salon, Medscape, Healthline, Epoch Times, MD Magazine, Specialty Pharmacy Times, Contagion Live.
English
Feature Stories
Investigative Journalism
Interview (Print / Radio / Podcast)
+1
Technology
Science & Environment
Health & Fitness
+3
Related Articles
New Case Report Links 1 Death to New FDA-Approved Alzheimer’s Drug
A clinical trial participant's death may be linked to the FDA-approved Alzheimer's drug lecanemab (Lequembi), according to a new case report. The drug, which targets amyloid plaques, received accelerated FDA approval but faced coverage rejection from the Center for Medicare & Medicaid Services (CMS) due to safety and effectiveness concerns. The case highlights the potential for fatal drug interactions and the need for thorough patient screening. Experts emphasize the importance of balancing treatment benefits and risks, while the Alzheimer's Association remains optimistic about new treatments. The CMS decision limits access to the costly drug, posing challenges for Medicaid recipients.
Balanced
Factuality Scale
Elizabeth Dickinson
Elizabeth Dickinson is a Deca journalist based in the Arabian Peninsula. Her writing has appeared in The New Yorker, Foreign Policy, The Economist, Politico Magazine, the Christian Science Monitor, the Wall Street Journal, the New York Times, and The Financial Times, among others. Elizabeth was ...
English
French
Spanish
Feature Stories
Content Writing
Corporate Content
+6
Fact Checking
Jobs Completed 7
Job Success Rate 88%
Related Articles
A conversation with CDC Director Rochelle P. Walensky
The article discusses the appointment of Rochelle P. Walensky as the new director of the CDC and her background in infectious diseases, including her work on HIV/AIDS and COVID-19. It covers her medical education at Johns Hopkins School of Medicine, her tenure at Massachusetts General Hospital, and her vision for addressing public health challenges, including the COVID-19 pandemic, structural inequities, and racism as a public health issue. The article also touches on her personal motivations and the influence of her mentors. Walensky's upcoming virtual conversation with Paul B. Rothman in the Johns Hopkins Health Policy Forum is mentioned, highlighting the importance of addressing various public health issues and the impact of the pandemic on different aspects of healthcare.
Umar Farooq
Umar Farooq is a journalist based in Istanbul, Turkey. He reports regularly for the Los Angeles Times from the region. In the past year, his work has also appeared in Foreign Affairs, National Geographic, The Guardian, Boston Review, and The Nation. He received a Pulitzer Center Crisis ...
Arabic
English
Turkish
+1
Audio package (Radio / Podcast)
Vox Pop
Feature Stories
+5
Politics
War Reporter
Investigative Reporting
+3
Jobs Completed 4
Related Articles
Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks
Wall Street analysts have recently trimmed price targets for several stocks, including Tesla, Ovintiv, Chevron Corporation, Devon Energy Corporation, and Exxon Mobil Corporation, reflecting recalibrated expectations amid market dynamics. The Federal Reserve's stance against anticipated interest rate cuts has influenced market sentiment, leading to significant declines in Asian stocks. China's economy is poised for favorable conditions in 2024, with policies aimed at sustained consumption growth. Analysts maintain a bearish outlook on pharmaceutical stocks like Biogen, Pfizer, and Apellis Pharmaceuticals.
Informative
Factuality Scale
Gaby Galvin
I am a freelance journalist based in Aarhus, Denmark. I previously spent five years in Washington, D.C., covering public health, policy and industry issues such as the COVID-19 pandemic, maternal mortality, addiction and mental health. My work has appeared in Smart Cities Dive, Morning Consult and ...
English
Journalism
Politics
Jobs Completed 2
Usually Responds Within an hour
Related Articles
Incoming PhRMA Chair Expects Drugmakers to Face ‘Some Pain’ in 2022 Amid Reform and Efforts to Rebuild Patient Trust
Ramona Sequeira, incoming chair of the Pharmaceutical Research and Manufacturers of America (PhRMA) and president of Takeda Pharmaceutical's U.S. business, anticipates significant changes in the pharmaceutical industry in 2022 amid ongoing drug pricing reforms. Sequeira emphasizes the need to balance innovation with common-sense reforms to lower patient costs and rebuild trust in the industry. Key issues include Medicare Part D restructuring, opposition to Medicare negotiating drug prices, and efforts to increase diversity in clinical trials. The industry faces a complex landscape of regulatory changes and patient access challenges, with a focus on collaboration and patient-centric approaches.
Balanced
Factuality Scale
Center-Left
Political View
Benjamin Jacobs
Benjamin Jacobs is a journalist based in London, United Kingdom.
Jobs Completed 3
Related Articles
Epidemiology of Epstein-Barr Virus infection and Infectious Mononucleosis in the United Kingdom
The study investigates the epidemiology of Epstein-Barr Virus (EBV) infection and infectious mononucleosis in the United Kingdom. It acknowledges the support from various pharmaceutical companies and organizations, including Barts Charity and SEU. The research adheres to ethical guidelines and has obtained necessary approvals. The findings contribute to understanding the prevalence and impact of EBV in the UK.
Factual
Factuality Scale
Krista Mahr
Krista Mahr is a journalist reporting on Africa, based in Johannesburg. She is an active contributor to several news organizations including the Washington Post, the Financial Times, Newsweek, Bloomberg Businessweek, Associated Press and others. Mahr was previously based in New Delhi, where she ...
English
Live Reporting
Fact Checking
Investigative Reporting
Fact Checking
Related Articles
PBMs play defense on the Hill
Pharmacy benefit managers (PBMs) are under scrutiny from multiple congressional committees for their business practices and lack of transparency. The Senate Finance Committee aims to draft a bipartisan PBM bill by summer, while the House Energy and Commerce Health Subcommittee is holding a hearing on healthcare transparency. The Pharmaceutical Care Management Association is actively defending PBMs, arguing they help lower drug costs. Concurrently, the FDA has approved a new ALS treatment by Biogen, and the President’s Malaria Initiative is expanding to three more African countries. Additionally, Florida lawmakers are investigating medical organizations supporting gender-affirming treatments for minors.
Balanced
Factuality Scale
Center
Political View
Hélène Molinari
Hélène Molinari is a freelance journalist based in Paris, France. Writer and Editor.
French
Investigative Journalism
Fact Checking
Current Affairs
Technology
Science & Environment
+4
Related Articles
Where to Work When You Are a Woman: The Best Workplaces for Women 2021 Revealed
The article highlights the 'Best Workplaces for Women 2021' as recognized by Great Place To Work® France, emphasizing companies that excel in gender equality and workplace inclusion. The selection criteria included female representation in the workforce and management, perceptions of women in the workplace, and organizational practices supporting professional equality and parenthood. Notable companies like Intuit QuickBooks, Lesfurets, and BIOGEN are praised for their innovative and inclusive practices, such as equal recruitment efforts, anti-sexism campaigns, and leadership programs for women. The article underscores the commitment of both large and small enterprises to fostering a more inclusive work environment.
Informative
Factuality Scale
Laura Sanders
Laura is an award-winning journalist, travel writer and broadcaster based in the West Midlands, U.K. She has worked with the BBC, Conde Nast Traveller, Euronews, The Independent Travel, Lonely Planet and Which? Travel, among others. Laura is a regular on the Which? podcasts offering travel ...
English
Audio package (Radio / Podcast)
Interview (Video / Broadcast)
Feature Stories
+8
Food & Drink
Investigative Reporting
Research
+3
Jobs Completed 4
Related Articles
New Alzheimer’s drugs are coming. Here’s what you need to know
New Alzheimer's drugs, including donanemab, lecanemab, and aducanumab, show promise in slowing cognitive decline by targeting amyloid plaques in the brain. These drugs, which are monoclonal antibodies, offer temporary mental benefits but come with risks such as brain swelling and bleeding. The U.S. FDA recently approved lecanemab, while donanemab showed a 35% reduction in cognitive decline over 18 months. The drugs are not suitable for everyone and require close monitoring. Researchers hope these treatments will pave the way for more effective and safer options in the future.
Informative
Factuality Scale
Robin Seaton Jefferson
Robin Seaton Jefferson is a writer/reporter/journalist based in St. Louis, Missouri, United States of America, specializing in health care and health care technology, biographies, business writing and news for older adults. She has been a journalist in the St. Louis Metropolitan Area for 26 years ...
English
Feature Stories
Content Writing
Corporate Content
+4
Business
Finance
Politics
+17
Related Articles
New Alzheimer Treatment Could ‘Take The Brakes Off The Body’s Repair Systems’ Allowing It To Repair Itself
NervGen Pharma, based in Vancouver, is set to begin Phase 1 studies in early 2020 for a treatment targeting nerve damage and degenerative diseases, including Alzheimer’s disease. The company's technology, developed in collaboration with Dr. Jerry Silver from Case Western Reserve University, focuses on removing inhibitory effects of a protein called CSPG on the body's repair mechanisms. NervGen's lead candidate, NVG-291, aims to promote nerve regeneration and has shown promise in animal models. The treatment's potential for Alzheimer's is based on the presence of CSPG in disease plaques. With Alzheimer's affecting millions globally and lacking new effective treatments for over a decade, NervGen's approach represents a novel strategy in the field. The company plans to submit an Investigational New Drug application to the FDA and commence a Phase 2 multiple sclerosis clinical trial in early 2021.
Informative
Factuality Scale
Akanki Sharma
Akanki Sharma is a journalist.
English
Hindi
Feature Stories
Investigative Journalism
Interview (Print / Radio / Podcast)
+1
Politics
Technology
Social
+2
Related Articles
EMA seeks to issue guidance on liver damage from Novartis's gene therapy
The European Medicines Agency (EMA) is considering issuing guidance for physicians using Novartis's gene therapy Zolgensma, advising them to monitor patients for liver injury following recent deaths due to liver failure. Novartis reported two fatalities in August from acute liver failure after Zolgensma treatment, which is used for spinal muscular atrophy. The guidance, pending approval from EMA expert panels, suggests consulting specialists and adjusting corticosteroid regimens if patients do not respond adequately. Zolgensma, which costs over $2 million per patient, competes with Roche's Evrysdi and Biogen's Spinraza.
Informative
Factuality Scale
Candice Tang
Candice Tang is a multi-media journalist based in Hong Kong.
Chinese (Mandarin)
Interview (Video / Broadcast)
Documentaries
Photography
+2
Politics
Current Affairs
Social
+2
Jobs Completed 8
Job Success Rate 100%
Usually Responds Seldom
Related Articles
A first: a new clinical trial will compare stem cell therapy with the best biologics for the treatment of severe multiple sclerosis
The National Institutes of Health (NIH) is initiating a clinical trial to compare the effectiveness of autologous hematopoietic stem cell therapy (AHSCT) with the best available biologic drugs for treating severe multiple sclerosis (MS). AHSCT has shown promise in halting the progression of MS and potentially eliminating the need for lifelong medication. The trial, named BEAT-MS, will be led by Dr. Jeffrey A. Cohen and will enroll 156 patients across the US and UK, who will be followed for six years. The trial will also assess the cost-effectiveness of AHSCT compared to biologics, which can be expensive and have severe side effects. This research could pave the way for AHSCT to become a routine treatment for MS in the future.
Stephanie Zhang
Stephanie Zhang is a journalist based in Melbourne, Australia. View Stephanie's previous work on their website: ****
Chinese (Mandarin)
English
Audio package (Radio / Podcast)
Feature Stories
Content Writing
+7
Business
Politics
Current Affairs
+12
Usually Responds Within a day
Related Articles
Lecanemab May Reverse Alzheimer’s Disease, But 3 Deaths Raise Questions
The FDA granted accelerated approval to Leqembi, the seventh Alzheimer's drug, on January 6, 2023. Developed by Eisai and Biogen, Lecanemab (Leqembi's generic name) is the first anti-amyloid drug shown to improve cognitive function, with a 27% reduction in cognitive decline in an 18-month trial. However, safety concerns have arisen due to three deaths linked to brain hemorrhages in patients treated with Lecanemab, raising questions about the balance of efficacy and safety. The FDA has approved Leqembi for patients with mild cognitive impairment or mild dementia, the same population studied in clinical trials.
Informative
Factuality Scale